Cassava Sciences Files Definitive Proxy Statement

TL;DR

<b>Cassava Sciences, Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023.</b>

AI Summary

CASSAVA SCIENCES INC (FLNA) filed a Proxy Statement (DEF 14A) with the SEC on March 26, 2024. Filing type: DEF 14A (Definitive Proxy Statement). Reporting period: Fiscal year ended December 31, 2023. Filed as of date: March 26, 2024. Previous company name: PAIN THERAPEUTICS INC (changed March 9, 2000). Business address: 6801 N CAPITAL OF TEXAS HIGHWAY, BUILDING 1; SUITE 300, AUSTIN, TX 78731.

Why It Matters

For investors and stakeholders tracking CASSAVA SCIENCES INC, this filing contains several important signals. This filing is a standard procedural document required for public companies to provide information to shareholders regarding upcoming meetings and voting matters. The proxy statement details executive compensation, board nominations, and other corporate governance items, which are crucial for shareholder decision-making.

Risk Assessment

Risk Level: low — CASSAVA SCIENCES INC shows low risk based on this filing. The filing is a routine proxy statement and does not contain new financial or operational data that would indicate immediate risk.

Analyst Insight

Review the proxy statement for details on executive compensation, board composition, and any shareholder proposals to understand governance and potential strategic directions.

Key Numbers

• 2024-03-26 — Filed as of Date (DEF 14A filing date)
• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-05-09 — Conformed Period of Report (Proxy statement reporting period)
• 001-41905 — SEC File Number (Cassava Sciences' SEC file number)

Key Players & Entities

• CASSAVA SCIENCES INC (company) — Registrant
• PAIN THERAPEUTICS INC (company) — Former company name
• 2024-03-26 (date) — Filed as of date
• 2023-12-31 (date) — Fiscal year end
• 6801 N CAPITAL OF TEXAS HIGHWAY (address) — Business address
• AUSTIN (location) — Business address city
• TX (location) — Business address state
• 78731 (postal_code) — Business address zip

FAQ

Industry Context

Cassava Sciences, Inc. operates in the pharmaceutical preparations industry, focusing on the development of treatments for neurodegenerative diseases.

Regulatory Implications

This filing is a standard DEF 14A, a requirement under the Securities Exchange Act of 1934 for public companies to provide information to shareholders.

What Investors Should Do

1. Examine the executive compensation details to understand pay structures and incentives.
2. Review board member nominations and any related proposals for insights into leadership and strategy.
3. Identify any shareholder proposals and the company's stance on them.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure. No specific comparative data from a previous filing is presented in this extract.

Key Financial Figures

• $0.001 — utstanding, designated as Common Stock, $0.001 par value per share ("Common Stock"), a

Filing Documents

• sava20240104_def14a.htm (DEF 14A) — 644KB
• graph01.jpg (GRAPHIC) — 53KB
• p01.jpg (GRAPHIC) — 111KB
• p02.jpg (GRAPHIC) — 144KB
• smlogo.jpg (GRAPHIC) — 13KB
• 0001437749-24-009339.txt (&nbsp;) — 2136KB
• sava-20231231.xsd (EX-101.SCH) — 7KB
• sava-20231231_def.xml (EX-101.DEF) — 9KB
• sava-20231231_lab.xml (EX-101.LAB) — 19KB
• sava-20231231_pre.xml (EX-101.PRE) — 9KB
• sava20240104_def14a_htm.xml (XML) — 128KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 17

Executive Compensation and Other Matters

Executive Compensation and Other Matters 18 Report of the Compensation Committee of the Board of Directors 36 Report of the Audit Committee of the Board of Directors 37 Certain Relationships and Related Transactions 38 Other Matters 38 Cassava Sciences, Inc. 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731 ________________ PROXY STATEMENT ________________ INFORMATION CONCERNING SOLICITATION AND VOTING General The enclosed proxy is solicited on behalf of the Board of Directors of Cassava Sciences, Inc. (the "Company") for use at the Annual Meeting of Stockholders to be held virtually on Thursday, May 9, 2024, at 10:00 a.m., Central Time, (the "Annual Meeting") and at any adjournment(s) or postponement(s) thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting of Stockholders. The Company's principal executive offices are located at the address listed at the top of this page and the Company's telephone number is (512) 501-2444. The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Annual Report"), is being mailed together with these proxy solicitation materials to all stockholders entitled to vote. This proxy statement for the Annual Meeting (the "Proxy Statement"), the accompanying proxy card and the Annual Report will first be mailed on or about April 3, 2024 to all stockholders entitled to vote at the Annual Meeting. THE COMPANY SHALL PROVIDE WITHOUT CHARGE TO ANY STOCKHOLDER SOLICITED BY THESE PROXY SOLICITATION MATERIALS A COPY OF THE ANNUAL REPORT UPON REQUEST OF A STOCKHOLDER MADE IN WRITING TO CASSAVA SCIENCES, INC., 6801 N CAPITAL OF TEXAS HIGHWAY, BUILDING 1; SUITE 300, AUSTIN, TEXAS 78731, ATTENTION: INVESTOR RELATIONS. How can I attend the Annual Meeting? Only stockholders of record and beneficial owners of shares of our Common Stock as of the close of business on March 19, 2024 (the "Record Date") may attend and particip

View Full Filing

View this DEF 14A filing on SEC EDGAR